The AGGF1 Knockout NCI-H1703 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human NCI-H1703 lung squamous cell carcinoma line, providing a loss-of-function model for the AGGF1 gene. This product consists of a heterogeneous pool of edited cells with targeted disruption of AGGF1 expression, avoiding the clonal selection bias associated with single-cell-derived knockouts. The polyclonal format preserves the genomic diversity of the parental line while enabling robust assessment of AGGF1-dependent phenotypes in a cancer cell context.
NCI-H1703 is a widely used human lung squamous cell carcinoma cell line established from a primary tumor resection. These cells serve as an in vitro model for squamous cell lung cancer, retaining key characteristics of the malignancy, including pathways relevant to tumor angiogenesis. The line’s adherent growth and compatibility with standard culture conditions make it suitable for a range of functional assays, from signaling studies to tumor microenvironment investigations.
AGGF1 encodes an angiogenic factor induced by the TWEAK (TNFSF12) cytokine upon binding its receptor Fn14, which triggers NF-??B-mediated transcription. Elevated AGGF1 promotes endothelial cell proliferation and migration through activation of AKT and ERK signaling cascades, and it stimulates the expression of downstream pro-angiogenic factors such as VEGF. AGGF1 interacts directly with AKT and ERK, and its function is amplified under hypoxic conditions and by VEGF-mediated positive feedback, positioning it as a key node in angiogenic signaling networks.
In the NCI-H1703 background, disruption of AGGF1 abrogates TWEAK-induced pro-angiogenic signaling, creating a valuable model to dissect the contribution of tumor cell-derived angiogenic factors to endothelial cell behavior. This knockout system illuminates how lung squamous cell carcinoma cells may orchestrate neovascularization within the tumor microenvironment, offering insights into the interplay between TWEAK/Fn14/NF-??B signaling and downstream angiogenic outputs.
Researchers can employ this polyclonal knockout product for a variety of applications, including angiogenesis research, TWEAK/Fn14 pathway dissection, and lung cancer progression studies. Representative assays include western blotting and RT-qPCR to confirm target disruption, HUVEC tube formation and conditioned medium endothelial proliferation assays to evaluate paracrine angiogenic activity, migration and Matrigel plug assays for in vivo relevance, and RNA-seq for transcriptome-wide impact analysis. These tools support drug target validation and the identification of AGGF1-dependent pathways. For further information or technical support, please contact Ascent Research.
